• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Celgene Corporation

Celgene Corporation

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. bluebird bio Announces Pricing of Public Offering of Common Stock

    bluebird bio Announces Pricing of Public Offering of Common Stock

  2. S&P, Dow rattle cage on uncharted territory

    S&P, Dow rattle cage on uncharted territory

  3. UPDATE: S&P 500, Nasdaq retest major support

    UPDATE: S&P 500, Nasdaq retest major support

  4. UPDATE: Reynolds rises on buyout report; Delta gains altitude

    UPDATE: Reynolds rises on buyout report; Delta gains altitude

  5. Share Repurchase: Potential Signal of Undervaluation and Outperformance

    Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...

  6. An ETF for This Lagging Sector

    Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.

  7. Credit Market Outlook: Bonds Priced for the Benign

    Corporate credit spreads are fairly valued--albeit at the tight end of the range that we view as fairly valued.

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.